The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | COVID-19 in patients with hematologic malignancies
Lindsay Wilde, MD, Thomas Jefferson University, Philadelphia, PA shares the findings of an investigation into the clinical impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on patients with hematologic malignancies, including multiple myeloma, diffuse large B-cell lymphoma, and mantle cell lymphoma. Of the small cohort of 21 patients who contracted COVID-19, 20 required hospitalization, 7 were admitted to the ICU, 6 required intubation, and 3 patients died. The patients that died were above the age of 70 and were former smokers. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
